81 results about "Osmolar Concentration" patented technology

The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.

Disclosed are ophthalmic solutions such as packaging solutions for storing ophthalmic devices and lens care solutions for cleaning, disinfecting, rinsing and/or storing ophthalmic devices. The ophthalmic solutions contain at least a polymerization product obtained from a monomeric mixture comprising (a) a monomer bearing a center of permanent positive charge and (b) a non-ionic ethylenically unsaturated monomer, wherein the solution has an osmolality of at least about 200 mOsm/kg, and a pH of about 4 to about 9.

A packaging system for the storage of an ionic, hydrogel contact lens employs an aqueous packaging solution including a phosphorylcholine polymer. Preferably, the solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 8 and is heat sterilized.

The present invention relates to novel process for the preparation of glycoproteins by mammalian cell culture wherein the sialic acid content of the glycoprotein produced is controlled over a broad range of values by manipulating the cell culture environment. The invention provides for processes in which the sialic acid content of the glycoprotein is modified by changes in cell culture parameters which affect cell specific productivity. Preferred embodiments of the invention include cell culture processes in the osmolality of the cell culture is controlled as well as the concentration of a transcription enhancer during the production phase of the cell culture. The invention further provides for novel preparations of soluble type 1 tumor necrosis factor immunoglobulin G1 and their uses in the treatment of inflammatory or immune related disorders.

The present disclosure provides a method for culturing cells in exogenous lactic acid. Certain aspects of the present disclosure include the production of recombinant proteins, such as antibodies and fragments thereof. Certain aspects of the present disclosure also relate to methods of controlling lactic acid production, pH stability and osmolality in cell culture.

The present disclosure provides methods of generating germ layers from stem cells comprising culturing the stem cells in a culture medium having an osmolality less than 340 mOsm/kg. The present disclosure also includes a method to generate different cell lineages from the germ layers as well as to detect them by immunological methods. The present disclosure further provides methods for the generation, isolation, cultivation and propagation of committed progenitor cells and for the production of differentiated cells from the three germ layers. The present disclosure also provides culture media for use in inducing the three germ layers.

An apparatus and computerized method of intravenously monitoring a patient's blood chemistry transmits real time measurements to an electronically controlled closed loop system that auto-regulates blood osmolality and glucose level with medications infused through a catheter designed for such purpose. The closed loop system utilizes a glucose algorithm and an osmolality algorithm implemented in hardware and software to control the flow of dextrose, insulin and hypertonic saline to a patient in an effort to achieve better patient outcomes in instances of trauma, surgery and medical illnesses.

The present disclosure relates to a method of reducing heterogeneity in antibodies during culturing, wherein the heterogeneity is due to proportion of charge variant of the antibody. The disclosure also comprises a process of growing cells in a cell culture system that results in antibodies with the reduced heterogeneity. In one embodiment antibody heterogeneity is reduced by the addition of divalent transitional metal ions such as zinc (Zn²⁺) to the cell culture medium. In another embodiment antibody heterogeneity is reduced by decreasing the osmolality of the cell culture medium.

A pharmaceutical composition for the oral or parenteral administration of a compound of Formula (I) comprising an oil in water emulsion, wherein the oil phase comprises the free base of or a pharmaceutically acceptable salt thereof of a compound of Formula (I), and one or more surfactants which are soluble in the oil phase and/or the aqueous phase. The emulsion optionally contains one or more excipients that are soluble in the oil phase and/or the aqueous phase, such as pH modifying agents such as buffers, osmolality/tonicity modifying agents, emulsifying agents, water-soluble polymers, and preservatives. The compound of Formula (I) can be formulated as a solid material and stored until needed. Kits for forming the emulsion are provided. Prior to administration, the solid material can be reconstituted in an aqueous medium to form the emulsion.

The present invention is directed towards an aqueous lubricant composition comprising hyaluronic acid, organic acid, salts and water, and has a pH of between 5.5 and 7.0 and an osmolality between about 150 and 1,500 mOsm/kg. The lubricant surprisingly has long-lasting lubricity and low osmolality as compared to conventional lubricants on the market.

A method of treatment of cystic fibrosis and other pulmonary diseases identified by nitric oxide deficiency, comprising administration of a nebulized solution of citrulline and/or another nitric oxide precursor as an inhalable aerosol or an inhalable dry powder for targeted delivery into conducting and central airways. Citrulline or another nitric oxide precursor is formulated as a composition having predetermined limited volume, salinity, pH and osmolality. The composition is nebulized into an aerosol having a mass median aerodynamic diameter (MMAD) between 2 μm and 6 μm.

The present invention provides novel methods of cell staining, such as bovine sperm, using electroporation or osmolality treatments at viability-enhancing temperatures. Furthermore, methods of highly efficient cell sorting that are especially suitable in sorting bovine sperm using novel cell staining procedures are also provided.

In this invention, a cell parameter, for example cell volume, is determined by subjecting one or more aliquots of a sample cell suspension to one or more alterations of at least one parameter of the cell environment to identify a point at which the cells achieve a particular shape to obtain a sample specific shape compensation factor. Preferably, the environmental parameter change is a reduction in osmolality.

An aqueous ophthalmic composition comprising a branched glycerol compound selected from the group consisting of a branched, glycerol monoalkyl ether, a branched, glycerol monoalkyl amine, a branched, glycerol monoalkyl sulfide, or any mixture thereof, present in a total amount of from 0.05 ppm to 1,000 ppm; a cationic antimicrobial component, and having an osmolality in a range from 200 mOsmol/kg to 400 mOsmol/kg. The presence of the branched glycerol compound enhances the biocidal efficacy of the aqueous ophthalmic composition containing one or more cationic antimicrobial components.

The invention provides a detection method of polyacrylamide concentration in a tertiary oil recovery liquid. The method comprises: drawing a standard curve, preparing standard polyacrylamide solutions of different concentrations, shearing for at least 30 seconds under rotate speeds of 11000-22000 r/min, determining light absorption values of the solutions, drawing a standard curve, detecting to-be-detected samples, determining light absorption values of the to-be-detected samples, and determining the concentration of the polyacrylamide of the samples referring to the drawed standard curve, wherein a nephelometry or a starch-cadmium iodide method is used to determine the light absorption values of the solutions. According to the invention, the method can eliminate relatively large errors of polymer concentrations of the recovery liquid determined by the traditional nephelometry and the starch-cadmium iodide methods, thereby increasing a detection precision of the polymer concentrations of the recovery liquid.